Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REPEVAX after REVAXIS · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| REPEVAX® after REVAXIS® | EXPERIMENTAL | REVAXIS® at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28). |
| REPEVAX® after Placebo | ACTIVE_COMPARATOR | Placebo at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28). |
| Name | Type | Description |
|---|---|---|
| REPEVAX® after REVAXIS® | BIOLOGICAL | Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after tetanus, diphtheria, poliomyelitis (inactivated) |
| REPEVAX® after Placebo | BIOLOGICAL | Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after placebo |
Inclusion Criteria: * Healthy adult, with vaccination history (by written evidence) of a minimum of 5 doses of a tetanus, diphtheria and poliomyelitis containing vaccine as recommended in the French vaccination calendar at 18 years old, and a maximum of 8 doses. * Last dose of a tetanus and/or diph...
REPEVAX is a vaccine used in healthy adults. It is given one month after REVAXIS to assess safety. The drug is being studied in a Phase 3 clinical trial in France.
REPEVAX is developed by Sanofi, a company traded under the ticker SNY. The drug is currently in Phase 3 clinical development for use in healthy adults.
REPEVAX is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 3 trial has been completed.
REPEVAX has one completed Phase 3 trial, NCT00400309, titled 'Safety of REPEVAX® Given One Month After REVAXIS®'. The trial enrolled 500 healthy adults in France and was randomized, double-blind, and active-controlled.
No, REPEVAX and REVAXIS are different vaccines. The clinical trial NCT00400309 studies the safety of giving REPEVAX one month after REVAXIS, indicating they are separate products used in sequence.